SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 247 filers reported holding SAGE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.22 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $22,514,520 | +43668.5% | 1,094,000 | 0.0% | 1.20% | -49.7% |
Q2 2023 | $51,440 | +12.1% | 1,094,000 | 0.0% | 2.39% | +5.8% |
Q1 2023 | $45,904 | -99.9% | 1,094,000 | 0.0% | 2.26% | +2.5% |
Q4 2022 | $41,725,160 | -2.6% | 1,094,000 | 0.0% | 2.20% | -8.7% |
Q3 2022 | $42,841,000 | +21.2% | 1,094,000 | 0.0% | 2.41% | +7.6% |
Q2 2022 | $35,336,000 | -2.4% | 1,094,000 | 0.0% | 2.24% | +20.3% |
Q1 2022 | $36,211,000 | -22.2% | 1,094,000 | 0.0% | 1.86% | +2.9% |
Q4 2021 | $46,539,000 | -4.0% | 1,094,000 | 0.0% | 1.81% | +6.8% |
Q3 2021 | $48,475,000 | -22.0% | 1,094,000 | 0.0% | 1.69% | -22.8% |
Q2 2021 | $62,150,000 | -24.1% | 1,094,000 | 0.0% | 2.19% | -21.0% |
Q1 2021 | $81,886,000 | -13.5% | 1,094,000 | 0.0% | 2.78% | -8.7% |
Q4 2020 | $94,642,000 | +41.5% | 1,094,000 | 0.0% | 3.04% | +31.6% |
Q3 2020 | $66,865,000 | +47.0% | 1,094,000 | 0.0% | 2.31% | +15.6% |
Q2 2020 | $45,489,000 | +3.4% | 1,094,000 | -28.6% | 2.00% | -33.3% |
Q1 2020 | $44,014,000 | +74.2% | 1,532,510 | +337.9% | 3.00% | +109.9% |
Q4 2019 | $25,267,000 | – | 350,000 | – | 1.43% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Finepoint Capital LP | 475,600 | $15,362,000 | 5.31% |
Integral Health Asset Management, LLC | 412,257 | $13,316,000 | 2.74% |
Palo Alto Investors LP | 851,409 | $27,501,000 | 2.40% |
Boxer Capital, LLC | 1,094,000 | $35,336,000 | 2.24% |
DAFNA Capital Management LLC | 180,306 | $5,824,000 | 1.59% |
Ikarian Capital, LLC | 250,000 | $8,075,000 | 1.47% |
Bellevue Group AG | 2,973,178 | $96,034,000 | 1.36% |
SECTOR GAMMA AS | 118,476 | $3,827,000 | 0.86% |
Artal Group S.A. | 450,000 | $14,535,000 | 0.78% |
Diametric Capital, LP | 19,393 | $626,000 | 0.46% |